The study aimed to develop an integrative, multi-tool silico framework that prioritizes ESR2 variant classes, annotates their biological context, and evaluates their potential clinical relevance through pathway/regulatory analyses, as well as pan-cancer survival modeling. The gene discussed is ESR2; the disease is cancer.